Equities research analysts expect Kindred Biosciences Inc (NASDAQ:KIN) to announce earnings of ($0.35) per share for the current quarter, according to Zacks. Two analysts have issued estimates for Kindred Biosciences’ earnings, with the lowest EPS estimate coming in at ($0.38) and the highest estimate coming in at ($0.32). Kindred Biosciences posted earnings per share of ($0.39) in the same quarter last year, which suggests a positive year over year growth rate of 10.3%. The company is scheduled to report its next earnings report after the market closes on Tuesday, November 12th.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.
According to Zacks, analysts expect that Kindred Biosciences will report full year earnings of ($1.52) per share for the current year, with EPS estimates ranging from ($1.62) to ($1.37). For the next financial year, analysts expect that the company will report earnings of ($1.25) per share, with EPS estimates ranging from ($1.46) to ($0.88). Zacks’ earnings per share calculations are a mean average based on a survey of sell-side analysts that follow Kindred Biosciences.
KIN has been the subject of several research reports. B. Riley cut shares of Kindred Biosciences from a “buy” rating to a “neutral” rating and decreased their price objective for the company from $18.00 to $8.50 in a research note on Tuesday, July 16th. Zacks Investment Research upgraded shares of Kindred Biosciences from a “sell” rating to a “hold” rating in a research note on Saturday. HC Wainwright restated a “buy” rating and set a $19.00 price objective on shares of Kindred Biosciences in a research note on Wednesday, July 31st. BidaskClub upgraded shares of Kindred Biosciences from a “sell” rating to a “hold” rating in a research note on Tuesday, November 5th. Finally, ValuEngine raised shares of Kindred Biosciences from a “buy” rating to a “strong-buy” rating in a report on Tuesday, October 15th. Three equities research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the company’s stock. The stock has a consensus rating of “Buy” and an average price target of $14.28.
Several large investors have recently bought and sold shares of the company. Tower Research Capital LLC TRC purchased a new stake in Kindred Biosciences in the 3rd quarter worth $46,000. Gabelli Funds LLC increased its holdings in Kindred Biosciences by 23.1% in the 3rd quarter. Gabelli Funds LLC now owns 16,000 shares of the biopharmaceutical company’s stock worth $110,000 after acquiring an additional 3,000 shares in the last quarter. Teton Advisors Inc. grew its holdings in shares of Kindred Biosciences by 5.9% during the third quarter. Teton Advisors Inc. now owns 36,000 shares of the biopharmaceutical company’s stock worth $247,000 after buying an additional 2,000 shares in the last quarter. Dalton Greiner Hartman Maher & Co. purchased a new stake in shares of Kindred Biosciences during the third quarter worth $971,000. Finally, Morgan Stanley grew its holdings in shares of Kindred Biosciences by 67.4% during the second quarter. Morgan Stanley now owns 1,901,961 shares of the biopharmaceutical company’s stock worth $15,843,000 after buying an additional 765,748 shares in the last quarter. 68.18% of the stock is owned by hedge funds and other institutional investors.
NASDAQ KIN traded up $0.05 during trading on Friday, reaching $8.75. 89,700 shares of the company’s stock traded hands, compared to its average volume of 182,740. The company has a debt-to-equity ratio of 0.01, a current ratio of 11.36 and a quick ratio of 10.79. Kindred Biosciences has a 12-month low of $5.96 and a 12-month high of $14.00. The company’s 50 day simple moving average is $7.52 and its two-hundred day simple moving average is $7.81. The firm has a market cap of $345.30 million, a price-to-earnings ratio of -5.47 and a beta of 0.45.
Kindred Biosciences Company Profile
Kindred Biosciences, Inc, a commercial-stage biopharmaceutical company, focusing on developing therapies for pets. Its product pipeline consists of small molecules and biologics for a range of indications in dogs, cats, and horses. The company offers Mirataz, a mirtazapine transdermal ointment for the management of weight loss in cats.
Further Reading: Calculating net profit and net profit margin ratio
For more information about research offerings from Zacks Investment Research, visit Zacks.com